Abstract

Two years ago we concluded that after oral administration bromhexine (Bisolvon) disrupted mucopolysaccharide fibres in mucoid bronchial secretions, changing their flow properties, but that its value in chronic bronchitis, asthma or emphysema remained in doubt.¹ Since then more reports on the drug have appeared, and the makers now claim that Bisolvon helps chronic bronchitics ‘by thinning sputum, easing expectoration, improving pulmonary function and producing clinical improvement’.